Difference between revisions of "Team:NCTU Formosa"

Line 207: Line 207:
 
        <div class="photocontent3"><h2>What do we care</h2>
 
        <div class="photocontent3"><h2>What do we care</h2>
 
         
 
         
−
In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more people can afford it. Therefore, more people can be prescribed and treated, lowering the mortality rate of cancer.<br>
+
In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.<br>
 
             </div>
 
             </div>
 
      </div>
 
      </div>

Revision as of 14:55, 15 September 2015

1
The only thing we detect is everything.

Who are we

NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO devoted to developing detection technology by utilizing antibodies. In 2015, We cooperated with iGEM with Synthetic Biology to develop a brand new detection platform.

What's new

APOllO E.Cotector:
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.

What do we care

In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.